Sourced of - Dr John Campbell - https://www.youtube.com/watch?v=X-xss9K7kwQ Therapeutic Goods administration January 2021 https://www.tga.gov.au/sites/default/... Page 4 “Almost similar microscopic lung inflammation was observed in both challenged control and immunised animals (macaques) after the peak of infection (Days 7/8)” Challenged with infection, (unvaccinated) control animals Almost similar microscopic lung inflammation Challenged with infection, immunized (vaccinated) animals Almost similar microscopic lung inflammation Page 4 “There are no distribution and degradation data on the S antigen-encoding mRNA.” A new therapy that uses an intra-cellular pathway to use intracellular ribosomes We know from page 45 the lipid nanoparticles are systemically distributed, But the spike protein that the RNA produces, distribution not tested No data on how long the spike protein persists Page 5 “Antibodies and T cells in monkeys declined quickly over 5 weeks after the second dose of BNT162b2 (V9), raising concerns over long term immunity” Page 6 – A few unknowns were identified by the TGA “Short term protection studies, lack of pharmacokinetic data for the S antigen-encoding mRNA (BNT162b2 V9), suboptimal dosing interval in the repeat dose study, lack of repeat dose toxicity studies in a second species, and genotoxicity studies with the novel excipients, (a substance formulated alongside the active ingrediants) and lack of studies investigating potential for autoimmune diseases were noted.” Page 6 – Unknown go on “Long term immunity, vaccine induced autoimmune diseases were not studied in the nonclinical program” Page 8 “BNT162b2 immunisation also induced proinflammatory cytokines such as GM-CSF, TNF-α, IL-6 and IL-18, in addition to IFN-γ, in splenocytes.”